How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review.

MLA

Remon, Jordi, et al. “How to Optimize the Incorporation of Immunotherapy in Trials for Oligometastatic Non-Small Cell Lung Cancer: A Narrative Review.” Translational Lung Cancer Research, vol. 10, no. 7, July 2021, pp. 3486–502. EBSCOhost, https://doi.org/10.21037/tlcr-20-1065.

APA

Remon, J., Menis, J., Levy, A., De Ruysscher, D. K. M., & Hendriks, L. E. L. (2021). How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review. Translational Lung Cancer Research, 10(7), 3486–3502. https://doi.org/10.21037/tlcr-20-1065

Chicago

Remon, Jordi, Jessica Menis, Antonin Levy, Dirk K M De Ruysscher, and Lizza E L Hendriks. 2021. “How to Optimize the Incorporation of Immunotherapy in Trials for Oligometastatic Non-Small Cell Lung Cancer: A Narrative Review.” Translational Lung Cancer Research 10 (7): 3486–3502. doi:10.21037/tlcr-20-1065.